A Phase 2 interventional study of Alpelisib and Fulvestrant in Breast Cancer, sponsored by Novartis Pharmaceuticals. Completed at 94 sites in 19 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-01-13.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing alpelisib in Breast Neoplasms — 3 open to participants now, 12 under way, 2 of them phase 3. Alpelisib · Breast Neoplasms.
Among the 38 studies testing alpelisib in Breast Neoplasms, this one is the 2nd largest by enrollment, is the only one that started in 2017, is one of 15 in phase 2, and was the 18th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →3 of the 38 studies testing alpelisib in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
The Methodist Hospital Research Institute · Sites in United States
Ages 18+
Novartis Pharmaceuticals
By country, each count listing its studies:
Alpelisib: first FDA approval 2019 (PIQRAY), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, alpelisib is the treatment under test here. Read study by study →
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 19 · Phase 3 5
First in 2010; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 383 is above the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 44 across the 38 interventional studies. Of the 25 that completed or were terminated, 10 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 38 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
199 studies in Breast Neoplasms by Novartis: 16 open now, 30 under way, 4 of them phase 3. Of 160 finished, 74 (46%) have results posted.
Among the 199 studies in Breast Neoplasms by Novartis, this one is the 31st largest by enrollment of the 155 interventional ones that give a count, is one of 6 that started in 2017, is one of 39 in phase 2, and was the 128th registered.
Novartis’s Breast Neoplasms studies by the year they started, since 1998.
7 of the studies testing alpelisib in Breast Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05038735Phase 3Novartis PharmaceuticalsStudy to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. | 2027-01-28 |
| NCT04208178Phase 3Novartis PharmaceuticalsStudy of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation | 2027-02-26 |
| NCT05660083The Methodist Hospital Research InstituteAlpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) | 2026-12-01 |
| NCT04544189Novartis PharmaceuticalsStudy Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer | 2027-01-29 |
| NCT01872260Novartis PharmaceuticalsStudy of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer | 2027-02-26 |
Add all 7 to your calendar (.ics) → With an account.
Among the 38 studies testing alpelisib in Breast Neoplasms, from their registry updates:
Among Novartis’s 199 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This was a Phase II, multicenter, open-label, three-cohort, non-comparative study of alpelisib plus endocrine therapy (either fulvestrant or letrozole) in subjects (pre- and post-menopausal women and men) with HR-positive, HER2-negative aBC harboring PIK3CA mutation(s) in the tumor, whose disease had progressed on or after prior treatments.
The study comprised two phases:
Core Phase: included a treatment phase for all subjects from first subject first treatment (FSFT) until disease progression, unacceptable toxicity, or death until 18 months post last subject first treatment (LSFT) + 1 month safety follow-up (total 19 months post LSFT), discontinuation from the study treatment for any other reason, or sponsor terminates the study. At the start of the Core Phase, subjects were assigned to Cohort A, Cohort B, or Cohort C based on previous therapy as follows:
A total of 340 subjects were planned to be enrolled, with approximately 112 subjects in each cohort. In the Core Phase, 379 subjects were analyzed, with 127 subjects in Cohort A, 126 subjects in Cohort B, and 126 subjects in Cohort C. In the Extension Phase, 11 subjects were analyzed, with 1 subject in Cohort A and 10 subjects in Cohort C.
Key Inclusion Criteria: Subjects eligible for inclusion in the Core Phase of the study fulfilled the following key inclusion criteria:
Subjects with documented evidence of tumor progression on or after:
i. Cyclin-Dependent Kinase 4 and 6 inhibitor (CDK4/6i) treatment as last treatment regimen in Cohorts A and B.
ii. aromatase inhibitor (AI) treatment (either in or setting) and received systemic chemotherapy or ET (monotherapy or combination except CDK4/6i + AI) as last treatment regimen in Cohort C. Upon completion of enrollment of Cohort B, subjects who received CDK4/6i + fulvestrant as immediate prior therapy were eligible for Cohort C.
iii. No more than 2 prior anticancer therapies for aBC. iv. Received no more than 1 prior regimen of chemotherapy for the treatment of advanced/metastatic disease was permitted.
v. Recovered to grade 1 or better from any adverse events (AEs) related to previous anticancer therapy prior to study entry (except alopecia or other toxicities not considered a safety risk for the subject at the investigator's discretion).
Subjects with:
i. , i.e., at least 1 measurable lesion as per v1.1 criteria; or ii. If no measurable disease was present, at least 1 predominantly lytic bone lesion had to be present.
Key exclusion criteria were:
Subjects with central nervous system (CNS) involvement unless they met all of the following criteria:
i. At least 4 weeks from prior therapy completion (including radiation and/or surgery) to starting the study treatment, ii. Clinically stable CNS tumor at the time of screening untreated or without evidence of progressions for at least 4 weeks after treatment as determined by clinical examination and brain imaging (magnetic resonance imaging (MRI) or computed tomography (CT) during screening period and stable low dose of for 2 weeks prior to initiating study treatment.
Other inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who received any Cyclin-Dependent Kinases 4 and 6 inhibitor (CDK 4/6i) plus aromatase inhibitor (AI) as immediate prior treatment will receive alpelisib + fulvestrant
Drug: Alpelisib · Drug: Fulvestrant · Drug: Goserelin · Drug: Leuprolide
Patients who received any CDK 4/6i plus fulvestrant as immediate prior treatment will receive alpelisib + letrozole
Drug: Alpelisib · Drug: Letrozole · Drug: Goserelin · Drug: Leuprolide
Participants who received systemic chemotherapy or endocrine therapy (ET) (as monotherapy or in combination with targeted treatment except CDK 4/6i + AI) as immediate prior treatment will receive alpelisib + fulvestrant.
Drug: Alpelisib · Drug: Fulvestrant · Drug: Goserelin · Drug: Leuprolide
300 mg of alpelisib film-coated tablets administered orally once daily
Also known as: BYL719
500 mg of fulvestrant via intramuscular injection administered on Days 1, 15 on Cycle 1 and Day 1 at each cycle thereafter. Cycle=28 days
2.5 mg of letrozole film-coated tablets administered orally once daily
3.6 mg of goserelin via injectable subcutaneous implant administered every 28 days. Only for men in Cohort B and premenopausal women.
7.5 mg of leuprolide via injectable intramuscular depot administered every 28 days. Only for men in cohort B and premenopausal women.
Core Phase: Percentage of Participants Who Were Alive Without Disease Progression at 6 Months
Percentage of participants who were alive without disease progression at 6-month follow-up based on local investigator assessment per RECIST v1.1 in Cohort A, Cohort B and Cohort C. Participants who progressed, died, or discontinued study before 6 months were counted as a failure.
Time frame: At 6 months
Core Phase: Progression Free Survival (PFS)
PFS is defined as the time from the date of first dose of study medication to the date of the first documented progression or death due to any cause occurring in the study. PFS was assessed based on local investigator's assessment according to RECIST v1.1. PFS was censored if no PFS event was observed before the cut-off date. The censoring date was the date of last adequate tumor assessment before the cut-off date. If a PFS event was observed after two or more missing or non-adequate tumor assessments, then PFS was censored at the last adequate tumor assessment. PFS was estimated using the Kaplan-Meier method.
Time frame: From date of first dose to date of first documented progression or death, up to 46 months
Core Phase: Progression Free Survival on Next Line Treatment (PFS2)
PFS2 is defined as time from the date of first dose of study medication to the date of first documented progression on next-line therapy or death from any cause. The first documented progression on next-line treatment is based on investigator assessment of progressive disease. PFS2 was estimated using the Kaplan-Meier method.
Time frame: From date of first dose to date of first documented progression on next-line therapy or death, up to approximately 55 months
Core Phase: Overall Response Rate (ORR)
ORR is defined as the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR) based on local investigator's assessment according to RECIST v1.1 in each cohort. CR: Disappearance of all non-nodal target lesions and all non-target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm and all lymph nodes assigned as non-target lesions must be non-pathological in size (\<10 mm short axis) PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.
Time frame: Up to 46 months
Core Phase: Clinical Benefit Rate (CBR)
CBR is defined as the percentage of participants with a BOR of CR or PR or an overall lesion response of stable disease (SD) or Non-CR/ Non-PD lasting ≥ 24 weeks based on local investigator's assessment according to RECIST v1.1. CR: Disappearance of all non-nodal target lesions and all non-target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm and all lymph nodes assigned as non-target lesions must be non-pathological in size (\<10 mm short axis) PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. SD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease.
Time frame: Up to 46 months
Core Phase: Duration of Response (DOR)
DOR is the time from the date of first documented response (confirmed CR or PR based on local investigator's assessment according to RECIST v1.1) to the date of first documented progression or death due to underlying cancer. Subjects continuing without progression or death due to underlying cancer were censored at the date of their last adequate tumor assessment. DOR was estimated using the Kaplan-Meier method.
Time frame: From date of first documented response to first documented progression or death, up to 33.3 months
Core Phase: Overall Survival (OS)
OS is defined as the time of start of treatment to date of death or lost to follow-up. If a subject was not known to have died, then the OS data was censored at the date of the last known alive status for the patient.
Time frame: From date of first dose and up to approximately 55 months
Extension Phase: Percentage of Participants With Clinical Benefit as Assessed by the Investigator During the Extension Phase
Clinical Benefit Rate, as assessed by the Investigator during the Extension Phase, was defined as the proportion of patients with a best overall response of Complete Response (CR) or Partial Response (PR), or an overall lesion response of Stable Disease (SD) or non-complete response/non-progressive disease that lasted at least 24 weeks, based on the local investigator's assessment according to Response Evaluation Criteria in Solid Tumors version 1.1.
Time frame: Day 1 of each extension cycle up to Cycle 29 (each cycle lasting 28 days); median duration of exposure to study treatment (alpelisib or fulvestrant) = 41 months
This study was conducted in 92 centers across 19 countries
| Milestone | Cohort A: Pre-treated With CDK 4/6i + AI | Cohort B: Pre-treated With CDK 4/6i + Fulvestrant | Cohort C: Pre-treated With Systemic Chemotherapy or ET |
|---|---|---|---|
| Started | 127 | 126 | 126 |
| Completed | 1 | 0 | 10 |
| Not completed | 126 | 126 | 116 |
| Withdrew: Progressive disease | 89 | 88 | 90 |
| Withdrew: Adverse event | 20 | 14 | 13 |
| Withdrew: Physician decision | 7 | 13 | 5 |
| Withdrew: Subject/guardian decision | 5 | 8 | 4 |
| Withdrew: Death | 3 | 2 | 4 |
| Withdrew: Protocol deviation | 1 | 1 | 0 |
| Withdrew: Technical problems | 1 | 0 | 0 |
| Milestone | Cohort A: Pre-treated With CDK 4/6i + AI | Cohort B: Pre-treated With CDK 4/6i + Fulvestrant | Cohort C: Pre-treated With Systemic Chemotherapy or ET |
|---|---|---|---|
| Started | 1 | 0 | 10 |
| Completed | 0 | 0 | 5 |
| Not completed | 1 | 0 | 5 |
| Withdrew: Physician decision | 1 | 0 | 3 |
| Withdrew: Adverse event | 0 | 0 | 1 |
| Withdrew: Subject/guardian decision | 0 | 0 | 1 |
Percentage of participants who were alive without disease progression at 6-month follow-up based on local investigator assessment per RECIST v1.1 in Cohort A, Cohort B and Cohort C. Participants who progressed, died, or discontinued study before 6 months were counted as a failure.
| Percentage of participants | Cohort A: Pre-treated With CDK 4/6i + AI | Cohort B: Pre-treated With CDK 4/6i + Fulvestrant | Cohort C: Pre-treated With Systemic Chemotherapy or ET |
|---|---|---|---|
| Core Phase: Percentage of Participants Who Were Alive Without Disease Progression at 6 Months | 53.8 (44.41 to 62.96) | 46.5 (37.10 to 56.07) | 53.0 (43.51 to 62.41) |
PFS is defined as the time from the date of first dose of study medication to the date of the first documented progression or death due to any cause occurring in the study. PFS was assessed based on local investigator's assessment according to RECIST v1.1. PFS was censored if no PFS event was observed before the cut-off date. The censoring date was the date of last adequate tumor assessment before the cut-off date. If a PFS event was observed after two or more missing or non-adequate tumor assessments, then PFS was censored at the last adequate tumor assessment. PFS was estimated using the Kaplan-Meier method.
| Months | Cohort A: Pre-treated With CDK 4/6i + AI | Cohort B: Pre-treated With CDK 4/6i + Fulvestrant | Cohort C: Pre-treated With Systemic Chemotherapy or ET |
|---|---|---|---|
| Core Phase: Progression Free Survival (PFS) | 8.0 (5.6 to 8.6) | 5.6 (3.7 to 7.1) | 5.6 (5.4 to 8.1) |
PFS2 is defined as time from the date of first dose of study medication to the date of first documented progression on next-line therapy or death from any cause. The first documented progression on next-line treatment is based on investigator assessment of progressive disease. PFS2 was estimated using the Kaplan-Meier method.
| Months | Cohort A: Pre-treated With CDK 4/6i + AI | Cohort B: Pre-treated With CDK 4/6i + Fulvestrant | Cohort C: Pre-treated With Systemic Chemotherapy or ET |
|---|---|---|---|
| Core Phase: Progression Free Survival on Next Line Treatment (PFS2) | 15.2 (11.4 to 21.7) | 13.0 (10.2 to 13.9) | 13.5 (11.5 to 17.3) |
ORR is defined as the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR) based on local investigator's assessment according to RECIST v1.1 in each cohort. CR: Disappearance of all non-nodal target lesions and all non-target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm and all lymph nodes assigned as non-target lesions must be non-pathological in size (\<10 mm short axis) PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.
| Percentage of participants | Cohort A: Pre-treated With CDK 4/6i + AI | Cohort B: Pre-treated With CDK 4/6i + Fulvestrant | Cohort C: Pre-treated With Systemic Chemotherapy or ET |
|---|---|---|---|
| Core Phase: Overall Response Rate (ORR) | 19.3 (12.7 to 27.6) | 17.5 (11.1 to 25.8) | 25.2 (17.6 to 34.2) |
CBR is defined as the percentage of participants with a BOR of CR or PR or an overall lesion response of stable disease (SD) or Non-CR/ Non-PD lasting ≥ 24 weeks based on local investigator's assessment according to RECIST v1.1. CR: Disappearance of all non-nodal target lesions and all non-target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm and all lymph nodes assigned as non-target lesions must be non-pathological in size (\<10 mm short axis) PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. SD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease.
| Percentage of participants | Cohort A: Pre-treated With CDK 4/6i + AI | Cohort B: Pre-treated With CDK 4/6i + Fulvestrant | Cohort C: Pre-treated With Systemic Chemotherapy or ET |
|---|---|---|---|
| Core Phase: Clinical Benefit Rate (CBR) | 46.2 (37.0 to 55.6) | 35.1 (26.4 to 44.6) | 38.3 (29.4 to 47.8) |
DOR is the time from the date of first documented response (confirmed CR or PR based on local investigator's assessment according to RECIST v1.1) to the date of first documented progression or death due to underlying cancer. Subjects continuing without progression or death due to underlying cancer were censored at the date of their last adequate tumor assessment. DOR was estimated using the Kaplan-Meier method.
| Months | Cohort A: Pre-treated With CDK 4/6i + AI | Cohort B: Pre-treated With CDK 4/6i + Fulvestrant | Cohort C: Pre-treated With Systemic Chemotherapy or ET |
|---|---|---|---|
| Core Phase: Duration of Response (DOR) | 13.8 (5.5 to 19.4) | 6.5 (5.4 to 9.4) | 16.5 (8.3 to 22.2) |
OS is defined as the time of start of treatment to date of death or lost to follow-up. If a subject was not known to have died, then the OS data was censored at the date of the last known alive status for the patient.
| Months | Cohort A: Pre-treated With CDK 4/6i + AI | Cohort B: Pre-treated With CDK 4/6i + Fulvestrant | Cohort C: Pre-treated With Systemic Chemotherapy or ET |
|---|---|---|---|
| Core Phase: Overall Survival (OS) | 27.3 (21.3 to 32.7) | 29.0 (24.5 to 34.8) | 20.7 (16.9 to 28.1) |
Clinical Benefit Rate, as assessed by the Investigator during the Extension Phase, was defined as the proportion of patients with a best overall response of Complete Response (CR) or Partial Response (PR), or an overall lesion response of Stable Disease (SD) or non-complete response/non-progressive disease that lasted at least 24 weeks, based on the local investigator's assessment according to Response Evaluation Criteria in Solid Tumors version 1.1.
| Participants | All Patients in Extension Phase |
|---|---|
| Extension Cycle 1 Day 1 | 8 |
| Extension Cycle 2 Day 1 | 7 |
| Extension Cycle 3 Day 1 | 7 |
| Extension Cycle 4 Day 1 | 6 |
| Extension Cycle 5 Day 1 | 8 |
| Extension Cycle 6 Day 1 | 7 |
| Extension Cycle 7 Day 1 | 7 |
| Extension Cycle 8 Day 1 | 6 |
| Extension Cycle 9 Day 1 | 7 |
| Extension Cycle 10 Day 1 | 5 |
| Extension Cycle 11 Day 1 | 4 |
| Extension Cycle 12 Day 1 | 7 |
| Extension Cycle 13 Day 1 | 4 |
| Extension Cycle 14 Day 1 | 5 |
| Extension Cycle 15 Day 1 | 4 |
| Extension Cycle 16 Day 1 | 3 |
| Extension Cycle 17 Day 1 | 3 |
| Extension Cycle 18 Day 1 | 3 |
| Extension Cycle 19 Day 1 | 3 |
| Extension Cycle 20 Day 1 | 3 |
| Extension Cycle 21 Day 1 | 3 |
| Extension Cycle 22 Day 1 | 3 |
| Extension Cycle 23 Day 1 | 3 |
| Extension Cycle 24 Day 1 | 2 |
| Extension Cycle 25 Day 1 | 2 |
| Extension Cycle 26 Day 1 | 2 |
| Extension Cycle 27 Day 1 | 2 |
| Extension Cycle 28 Day 1 | 2 |
| Extension Cycle 29 Day 1 | 1 |
Collected over Adverse Events (AEs) were collected from the first dose through post-treatment follow-up, for up to 86 months. Deaths were recorded from study start through post-treatment follow-up over the same period. AE data were summarized for core phase patients from start to end of the core phase (up to 58 months) and for extension phase patients from the start of the core phase through the end of the extension phase (up to 86 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A: Pre-treated With CDK 4/6i + AI (Core Phase) | 78/127 (61.4%) | 37/127 (29.1%) | 126/127 (99.2%) |
| Cohort B: Pre-treated With CDK 4/6i + Fulvestrant (Core Phase) | 76/126 (60.3%) | 48/126 (38.1%) | 126/126 (100%) |
| Cohort C: Pre-treated With Systemic Chemotherapy or ET (Core Phase) | 67/126 (53.2%) | 38/126 (30.2%) | 124/126 (98.4%) |
| Cohort A: Pre-treated With CDK 4/6i + AI (Extension Phase) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Cohort B: Pre-treated With CDK 4/6i + Fulvestrant (Extension Phase) | — | — | — |
| Cohort C: Pre-treated With Systemic Chemotherapy or ET (Extension Phase) | 1/10 (10%) | 3/10 (30%) | 10/10 (100%) |
| Event | Cohort A: Pre-treated With CDK 4/6i + AI (Core Phase) | Cohort B: Pre-treated With CDK 4/6i + Fulvestrant (Core Phase) | Cohort C: Pre-treated With Systemic Chemotherapy or ET (Core Phase) | Cohort A: Pre-treated With CDK 4/6i + AI (Extension Phase) | Cohort B: Pre-treated With CDK 4/6i + Fulvestrant (Extension Phase) | Cohort C: Pre-treated With Systemic Chemotherapy or ET (Extension Phase) |
|---|---|---|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 0/127 | 0/126 | 1/126 | 0/1 | — | 1/10 |
| Ankle fractureInjury, poisoning and procedural complications | 0/127 | 1/126 | 0/126 | 0/1 | — | 1/10 |
| Migraine with auraNervous system disorders | 0/127 | 0/126 | 1/126 | 0/1 | — | 1/10 |
| HyperglycaemiaMetabolism and nutrition disorders | 7/127 | 3/126 | 2/126 | 0/1 | — | 0/10 |
| Abdominal painGastrointestinal disorders | 2/127 | 4/126 | 0/126 | 0/1 | — | 0/10 |
| PneumoniaInfections and infestations | 1/127 | 4/126 | 2/126 | 0/1 | — | 0/10 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/127 | 3/126 | 1/126 | 0/1 | — | 0/10 |
| Back painMusculoskeletal and connective tissue disorders | 0/127 | 0/126 | 3/126 | 0/1 | — | 0/10 |
| Acute kidney injuryRenal and urinary disorders | 0/127 | 3/126 | 1/126 | 0/1 | — | 0/10 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/127 | 2/126 | 2/126 | 0/1 | — | 0/10 |
| Event | Cohort A: Pre-treated With CDK 4/6i + AI (Core Phase) | Cohort B: Pre-treated With CDK 4/6i + Fulvestrant (Core Phase) | Cohort C: Pre-treated With Systemic Chemotherapy or ET (Core Phase) | Cohort A: Pre-treated With CDK 4/6i + AI (Extension Phase) | Cohort B: Pre-treated With CDK 4/6i + Fulvestrant (Extension Phase) | Cohort C: Pre-treated With Systemic Chemotherapy or ET (Extension Phase) |
|---|---|---|---|---|---|---|
| Dry eyeEye disorders | 7/127 | 6/126 | 5/126 | 1/1 | — | 1/10 |
| DiarrhoeaGastrointestinal disorders | 82/127 | 86/126 | 68/126 | 1/1 | — | 7/10 |
| DyspepsiaGastrointestinal disorders | 19/127 | 13/126 | 13/126 | 1/1 | — | 2/10 |
| Gastrointestinal painGastrointestinal disorders | 2/127 | 0/126 | 0/126 | 1/1 | — | 0/10 |
| NauseaGastrointestinal disorders | 59/127 | 68/126 | 51/126 | 1/1 | — | 3/10 |
| StomatitisGastrointestinal disorders | 34/127 | 43/126 | 38/126 | 1/1 | — | 3/10 |
| AstheniaGeneral disorders | 24/127 | 27/126 | 15/126 | 1/1 | — | 2/10 |
| Blood creatinine increasedInvestigations | 15/127 | 12/126 | 8/126 | 1/1 | — | 2/10 |
| Lymphocyte count decreasedInvestigations | 4/127 | 2/126 | 4/126 | 1/1 | — | 0/10 |
| Weight decreasedInvestigations | 18/127 | 19/126 | 23/126 | 1/1 | — | 2/10 |
| Age, Categorical(Participants) | Cohort A: Pre-treated With CDK 4/6i + AI | Cohort B: Pre-treated With CDK 4/6i + Fulvestrant | Cohort C: Pre-treated With Systemic Chemotherapy or ET | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 95 | 80 | 83 | 258 |
| >=65 years | 32 | 46 | 43 | 121 |
| Sex: Female, Male(Participants) | Cohort A: Pre-treated With CDK 4/6i + AI | Cohort B: Pre-treated With CDK 4/6i + Fulvestrant | Cohort C: Pre-treated With Systemic Chemotherapy or ET | Total |
|---|---|---|---|---|
| Female | 127 | 126 | 125 | 378 |
| Male | 0 | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | Cohort A: Pre-treated With CDK 4/6i + AI | Cohort B: Pre-treated With CDK 4/6i + Fulvestrant | Cohort C: Pre-treated With Systemic Chemotherapy or ET | Total |
|---|---|---|---|---|
| Caucasian | 81 | 85 | 83 | 249 |
| Unknown | 23 | 24 | 11 | 58 |
| Asian | 12 | 8 | 28 | 48 |
| Black | 6 | 1 | 1 | 8 |
| Other | 3 | 7 | 3 | 13 |
| Pacific islander | 1 | 0 | 0 | 1 |
| Missing | 1 | 1 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Aug 2017 to primary completion in Jun 2021, 45 months.
Results were first posted in Mar 2024, 2 years 9 months after primary completion. A results delay was requested in May 2022.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 45 months is above that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Alpelisib · Letrozole